Literature DB >> 8045495

A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies.

M Chevallier1, S Guerret, P Chossegros, F Gerard, J A Grimaud.   

Abstract

The evaluation of hepatic fibrosis on histological sections is of great interest for the staging and follow-up of chronic liver disease. Because no reliable scoring system is yet available, we have designed a semiquantitative scoring system in which the four main sites of fibrotic deposit--centrilobular vein, portal tract and perisinusoidal space, together with width and number of septa when present--are analyzed. These different items have been previously settled from comparison with morphometric measurements to evaluate surface density of total collagen performed on the same liver needle biopsy specimens stained with picro-sirius. The score has been tested on samples from 200 consecutive patients with various liver diseases and compared with the surface density of total collagen and Knodell scoring system. For observer variation study, the features by three independent pathologists were coded on 20 cases. There was a good interobserver (Kendall's tau-b = 0.75) and intraobserver (tau-B = 0.73) reproducibility. Each component of the fibrosis scoring system and total collagen surface density were significantly linearly related (one-way polynomial analysis, p < 10(-4); the correlation between semiquantitative scoring system and surface density of total collagen was 0.73 (p < 10(-5). Our semiquantitative scoring system, simple and reproducible, describes both liver architecture and fibrotic deposit. It is better related to morphometric measurement of fibrosis than each of its constituents or than the fibrosis item of the Knodell scoring system. It represents a reliable and convenient method for fibrosis evaluation, which is mandatory for clinical use.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8045495

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  51 in total

Review 1.  [Bioptic diagnosis of chronic hepatitis. Results of an evidence-based consensus conference of the German Society of Pathology, of the German Society for Digestive and Metabolic Diseases and of Compensated Hepatitis (HepNet)].

Authors:  P Schirmacher; W E Fleig; A Tannapfel; C Langner; V Dries; L Terracciano; H Denk; H P Dienes
Journal:  Pathologe       Date:  2004-09       Impact factor: 1.011

2.  Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis.

Authors:  Yong-Ping Yang; Xue-Mei Ma; Chun-Ping Wang; Jun Han; Yin-Ying Lu; Yi Xiang; Shu-Hui Su; Yong-Yi Feng
Journal:  World J Gastroenterol       Date:  2006-02-07       Impact factor: 5.742

Review 3.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

4.  Effects of total glucosides of peony on immunological hepatic fibrosis in rats.

Authors:  Hua Wang; Wei Wei; Ni-Ping Wang; Cheng-Yi Wu; Shang-Xue Yan; Li Yue; Ling-Ling Zhang; Shu-Yun Xu
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

5.  Real-time tissue elastography (RTE) for noninvasive evaluation of fibrosis in liver diseases in children in comparison to liver biopsy.

Authors:  Jens-Peter Schenk; Buket Selmi; Christa Flechtenmacher; Saroa El Sakka; Ulrike Teufel; Guido Engelmann
Journal:  J Med Ultrason (2001)       Date:  2014-05-25       Impact factor: 1.314

Review 6.  Current research of hepatic cirrhosis in China.

Authors:  Xi-Xian Yao; Shu-Lin Jiang; Dong-Mei Yao
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

7.  Feasibility of histological grading and staging of chronic viral hepatitis using specimens obtained by thin-needle biopsy.

Authors:  Daniela Petz; Sabine Klauck; Friedrich-Wilhelm Röhl; Peter Malfertheiner; Albert Roessner; Christoph Röcken
Journal:  Virchows Arch       Date:  2003-01-28       Impact factor: 4.064

8.  Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model.

Authors:  Susanne Mende; Sigrid Schulte; Ingo Strack; Heike Hunt; Margarete Odenthal; Galyna Pryymachuck; Maria Quasdorff; Münevver Demir; Dirk Nierhoff; Hans-Peter Dienes; Tobias Goeser; Hans-Michael Steffen; Ulrich Töx
Journal:  Dig Dis Sci       Date:  2012-12-18       Impact factor: 3.199

9.  Role of CTGF gene promoter methylation in the development of hepatic fibrosis.

Authors:  Cuicui Shi; Guangming Li; Yanyan Tong; Yilin Deng; Jiangao Fan
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

10.  Long-term outcome of liver resection for hepatocellular carcinoma in noncirrhotic nonfibrotic liver with no viral hepatitis or alcohol abuse.

Authors:  Jean Lubrano; Emmanuel Huet; Basile Tsilividis; Arnaud François; Odile Goria; Ghassan Riachi; Michel Scotté
Journal:  World J Surg       Date:  2008-01       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.